IFNα treatment generates antigen-presenting cells insensitive to atorvastatin inhibition of MHC-II expression

Clinical Immunology

Volumn 129, Issue 2, 2008, Pages 350-359

  López, Patricia ^a   Gutiérrez, Carmen ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Atorvastatin; Dendritic cells; IFN alpha

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; CD14 ANTIGEN; CD86 ANTIGEN; DIFFERENTIATION ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T6 ANTIGEN; HEPTANOIC ACID DERIVATIVE; HLA ANTIGEN CLASS 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPTANOIC ACIDS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-ALPHA; INTERLEUKIN-4; MONOCYTES; PYRROLES; T-LYMPHOCYTES;

EID: 53749097590     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.07.010     Document Type: Article

References (50)

1. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 (2001) 661-664
2. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
3. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
4. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., and Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5 (1999) 919-923
5. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., and Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835-1837
6. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H., Sawa Y., Mizuno M., Kagawa K., and Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25 (1996) 283-291
7. Ronnblom L.E., Alm G.V., and Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid-tumors. Ann. Intern. Med. 115 (1991) 178-183
8. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-336
9. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., and Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2610-2615
10. Dall'era M.C., Cardarelli P.M., Preston B.T., Witte A., and Davis Jr. J.C. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64 (2005) 1692-1697
11. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., Ly N., Woodward R.N., Fry K.E., Lau A.Y., Prentice J.G., Wohlgemuth J.G., and Crow M.K. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3958-3967
12. Dauer M., Schad K., Junkmann J., Bauer C., Herten J., Kiefl R., Schnurr M., Endres S., and Eigler A. IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J. Leukoc. Biol. 80 (2006) 278-286
13. Lapenta C., Santini S.M., Spada M., Donati S., Urbani F., Accapezzato D., Franceschini D., Andreotti M., Barnaba V., and Belardelli F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36 (2006) 2046-2060
14. Radvanyi L.G., Banerjee A., Weir M., and Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J. Immunol. 50 (1999) 499-509
15. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., and Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191 (2000) 1777-1788
16. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., and Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64 (1998) 358-367
17. Santini S.M., Di Pucchio T., Lapenta C., Parlato S., Logozzi M., and Belardelli F. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 21 (2003) 357-362
18. Dauer M., Pohl K., Obermaier B., Meskendahl T., Robe J., Schnurr M., Endres S., and Eigler A. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology 110 (2003) 38-47
19. Mcrae B.L., Nagai T., Semnani R.T., van Seventer J.M., and van Seventer G.A. Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood 96 (2000) 210-217
20. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15 (2003) 138-147
21. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
22. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., and Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180 (1994) 83-93
23. Thurnher M., Zelle-Rieser C., Ramoner R., Bartsch G., and Holtl L. The disabled dendritic cell. FASEB J. 15 (2001) 1054-1061
24. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
25. Kwak B., Mulhaupt F., Veillard N., Pelli G., and Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly. 131 (2001) 41-46
26. Bessler H., Salman H., Bergman M., Straussberg R., and Djaldetti M.M. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin. Immunol. 117 (2005) 73-77
27. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
28. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., and Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 (2001) 990-997
29. Riboldi P., Gerosa M., and Meroni P.L. Statins and autoimmune diseases. Lupus 14 (2005) 765-768
30. Danciger J.S., Lutz M., Hama S., Cruz D., Castrillo A., Lazaro J., Phillips R., Premack B., and Berliner J. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J. Immunol. Methods 288 (2004) 123-134
31. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
32. Brumeanu T.D., Goldstein R., and Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol. 119 1 (2006) 1-12
33. Palinski W. Immunomodulation: a new role for statins?. Nat Med. 6 12 (2000) 1311-1312
34. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
35. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., and Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161 (1998) 1947-1953
36. Steinman R.M., Pack M., and Inaba K. Dendritic cell development and maturation. Adv. Exp. Med. Biol. 417 (1997) 1-6
37. Bender A., Sapp M., Schuler G., Steinman R.M., and Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196 (1996) 121-135
38. Reddy A., Sapp M., Feldman M., Subklewe M., and Bhardwaj N. Monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90 (1997) 3640-3646
39. Mohty M., Vialle-Castellano A., Nunes J.A., Isnardon D., Olive D., and Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171 (2003) 3385-3393
40. Banchereau J., Ueno H., Dhodapkar M., Connolly J., Finholt J.P., Klechevsky E., Blanck J.P., Johnston D.A., Palucka A.K., and Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34(+) progenitors and activated with type I interferon. J. Immunother. 28 (2005) 505-516
41. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002) 119-134
42. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., and Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003) 711-723
43. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., and Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 (2005) 1491-1503
44. Ji X., Cheung R., Cooper S., Li Q., Greenberg H.B., and He X.S. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37 3 (2003) 610-621 Erratum in: Hepatology 37(6) (2003) 1503
45. Sun D.X., and Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell. Immunol. 223 (2003) 52-62
46. Yilmaz A., Reiss C., Tantawi O., Weng A., Stumpf C., Raaz D., Ludwig J., Berger T., Steinkasserer A., Daniel W.G., and Garlichs C.D. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172 (2004) 85-93
47. Yilmaz A., Reiss C., Weng A., Cicha I., Stumpf C., Steinkasserer A., Daniel W.G., and Garlichs C.D. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 79 (2006) 529-538
48. Harris P.E., Malanga D., Liu Z., Hardy M.A., Souza F., Del Pozzo G., Winchester R.J., and Maffei A. Effect of interferon alpha on MHC class II gene expression in ex vivo human islet tissue. Biochim. Biophys. Acta. 1762 6 (2006) 627-635
49. Blank N., Schiller M., Krienke S., Busse F., Schätz B., Ho A.D., Kalden J.R., and Lorenz H.M. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J. Immunol. 179 6 (2007) 3613-3621
50. Kobayashi M., Azuma E., Ido M., Hirayama M., Jiang Q., Iwamoto S., Kumamoto T., Yamamoto H., Sakurai M., and Komada Y. A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells. J. Immunol. 167 (2001) 3585-3591